Sun Pharma's Q2FY24 Financial Performance Review
In this financial performance review, we delve into the results of Sun Pharma for the second quarter of fiscal year 2024 and analyze key metrics, including revenue, expenses, net profit, and margin.
| Particulars | Q2FY23 | YoY (% change) | Q1FY24 | QoQ (% change) | Q2FY24 |
| Total Income (₹crs.) | 11,037 | 13.13 | 12,145 | 2.81 | 12,486 |
| Total Expenses (₹crs.) | 8,625 | 12.41 | 9,341 | 3.79 | 9,695 |
| Net Profit (₹crs.) | 2,262 | 5 | 2,022 | 17.46 | 2,375 |
| Margin (%) | 20.49 | -1.47 | 16.65 | 2.37 | 19.02 |
REVENUE:
Sun Pharma reported a total income of ₹12,486 crores in the second quarter of fiscal year 2024, representing a growth of 2.81% compared sequentially. On a year-on-year (YoY) basis, there was substantial growth, with revenue increasing by 13.13%.
EXPENSES:
The company's total expenses for Q2FY24 amounted to ₹9,695 crores, indicating a modest increase of 3.79%. On a YoY basis, expenses increased by 12.41% from ₹8,625 crores in Q2FY23.
NET PROFIT:
In the second quarter of fiscal year 2024, Sun Pharma reported a net profit of ₹2,375 crores, signifying an impressive increase of 17.46% compared to the net profit of ₹2,022 crores in the preceding quarter. On a YoY basis, the company demonstrated growth in profitability, with a net profit of ₹2,262 crores in Q2FY23.
MARGINS: Sun Pharma's margin in Q2FY24 was 19.02%, representing a positive trend with an increase from the margin of 16.65% in the preceding quarter. Year-on-year, the margin showed a slight decline of -1.47%.
In conclusion, Sun Pharma's financial performance in the second quarter of fiscal year 2024 reflects strong revenue growth and increased profitability, both compared to the preceding quarter and on a YoY basis. The company's margins have also improved, signifying a healthy financial performance.
Stay tuned for more updates on upcoming financial performances.
